C. Farthing

D. Kuritzkes, C. Farthing, R. Steigbigel, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

A colour atlas of AIDS and HIV disease. 2nd edition.

C. Farthing, R. Staughton, Simon E. Brown, 2013 .

Papillitis and hepatitis B.

R. Howard, C. Farthing, R. Thin, 1986, British medical journal.

Kaposi's sarcoma in a patient after renal transplantation.

C. Farthing, A. Haleem, P. Little, 1983, Postgraduate medical journal.

Ritonavir and saquinavir combination therapy for the treatment of HIV infection.

R Rode, M Salgo, D. Ho, 1999, AIDS.

Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.

J. Lisziewicz, F. Lori, A. Foli, 2005, AIDS research and human retroviruses.

The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. The European-Australian Collaborative Group.

C. Farthing, D. Cooper, N. Clumeck, 1991, AIDS (London).

Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients

Brian P. Kearney, Calvin Cohen, Edwin DeJesus, 2006, Journal of acquired immune deficiency syndromes.

Co-administration of atazanavir with proton-pump inhibitors and H2 blockers.

C. Farthing, H. Khanlou, 2005, Journal of acquired immune deficiency syndromes.

Twice‐Daily Trizivir versus Combivir‐Abacavir in Antiretroviral‐Experienced Adults with Human Immunodeficiency Virus‐1 Infection: A Formulation‐Switch Trial

C. Farthing, M. Fischl, N. Bellos, 2003, Pharmacotherapy.

Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients.

J. Tolson, C. Farthing, M. Thompson, 2003, Journal of acquired immune deficiency syndromes.

Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.

C. Farthing, D. Cooper, S. Walmsley, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CLINICAL FINDINGS AND SEROLOGICAL EVIDENCE OF HTLV-III INFECTION IN HOMOSEXUAL CONTACTS OF PATIENTS WITH AIDS AND PERSISTENT GENERALISED LYMPHADENOPATHY IN LONDON

B. Gazzard, C. Farthing, A. Dalgleish, 1984, The Lancet.

Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.

B. Gazzard, C. Farthing, A. Dalgleish, 1987, AIDS.

Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.

C. Farthing, D. Shortino, B. Grinsztejn, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV-1 drug resistance in newly infected individuals.

Y. Cao, L. Zhang, A. Hurley, 1999, JAMA.

Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS

C. Farthing, B. Luft, J. Holden-Wiltse, 2001, AIDS.

Increased CD4+ T‐Lymphocyte Senescence Fraction in Advanced Human Immunodeficiency Virus Type 1 Infection

C. Farthing, E. Daar, S. Schneider, 1999, Scandinavian journal of immunology.

Idiopathic CD4+ T-lymphocytopenia--immunodeficiency without evidence of HIV infection.

R. Schooley, D. Ho, Y. Cao, 1993, The New England journal of medicine.

Efficacy of an Individualized Adherence Support Program with Contingent Reinforcement Among Nonadherent HIV-Positive Patients

C. Farthing, M. Javanbakht, Michael Weinstein, 2006, Journal of the International Association of Physicians in AIDS Care.

The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.

D. Hawkins, C. Farthing, M. Youle, 1989, The Quarterly journal of medicine.

Results of an Antiretroviral Adherence Intervention: STAR (Staying Healthy: Taking Antiretrovirals Regularly)

C. Farthing, W. Marelich, D. Murphy, 2007, Journal of the International Association of Physicians in AIDS Care.

Tipranavir: a novel second-generation nonpeptidic protease inhibitor

Vijayabhaskar R. Kandula, C. Farthing, H. Khanlou, 2005, Expert review of anti-infective therapy.

Peripheral Neuropathy Induced by Lopinavir-Saquinavir-Ritonavir Combination Therapy in an HIV-Infected Patient

C. Farthing, H. Khanlou, Miguel Valdes-Sueiras, 2007, Journal of the International Association of Physicians in AIDS Care.

Reduction of buffalo hump by switching to amprenavir in an HIV-infected patient.

C. Farthing, H. Khanlou, M. Adair, 2000, Archives of internal medicine.

Challenges of antiretroviral treatment in transient and drug-using populations: the SUN study.

C. Farthing, M. Sension, R. Pilson, 2001, AIDS patient care and STDs.

An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults

C. Farthing, E. Singer, A. Levine, 2008, Journal of clinical and experimental neuropsychology.

Herpes zoster, homosexuality and atopy

C. Farthing, J. Oates, C. Payne, 1984 .

SHINGLES IN SEVEN HOMOSEXUALS

C. Farthing, C. Payne, R. Staughton, 1984, The Lancet.

Two regimens of sultamicillin in treating uncomplicated gonorrhoea.

I. Phillips, C. Farthing, R. Thin, 1985, Genitourinary medicine.

Study on clinical epidemiology of male HIV/AIDS patients in a tertiary Chinese hospital, Shanghai, China.

C. Farthing, X. Jiang, H. Lu, 2013, Public health.

Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.

C. Farthing, H. Khanlou, E. Graham, 2002, AIDS.

Points: Pneumonia in the acquired immune deficiency syndrome

C. Farthing, 1985 .

Clinical investigations of lymphadenopathy, including lymph node biopsies, in 24 homosexual men with antibodies to the human T‐cell lymphotropic virus type III (HTLV‐III)

B. Gazzard, C. Farthing, K. Henry, 1986, The British journal of surgery.

Development of Kaposi sarcoma despite sustained suppression of HIV plasma viremia.

C. Farthing, H. Khanlou, T. Stein, 2000, Journal of acquired immune deficiency syndromes.

Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.

C. Farthing, A. Zolopa, J. Gallant, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Human immunodeficiency virus infection: a survey with special emphasis on mucocutaneous manifestations.

C. Farthing, A. Friedman-kien, 1990, Seminars in Dermatology.

Pilot study of directly observed therapy in highly nonadherent HIV-infected patients in an urban community-based institution.

Vijayabhaskar R. Kandula, C. Farthing, S. Sanchez, 2003, Journal of acquired immune deficiency syndromes.

Cutaneous metastasis (cancer en cuirasse and carcinoma erysipelatoides): a non-invasive search for the primary cancer using microscopical techniques on urine and skin.

C. Farthing, M. Leader, P. Copeman, 1985, Journal of the Royal Society of Medicine.

Heterogeneity of patients' adherence profile to antiretroviral therapy in HIV-infected patients.

C. Farthing, H. Khanlou, J. O'Malley, 2001, Journal of acquired immune deficiency syndromes.